A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2022-10-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Digoxin; Itraconazole; Rifampin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Must have a body mass index between 18 and 33 kg/m2 (inclusive)

• Adult female of nonchildbearing potential or male, any race or ethnicity, and in good health as determined by the medical history, physical exam, vital signs, 12-lead electrocardiogram, and clinical laboratory assessments

Exclusion Criteria:

• Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion

• Any major surgery within 4 weeks of the first dose administration

• History of drug abuse within 2 years of the first dose administration

Other protocol-defined inclusion/exclusion criteria apply